Omeros Shares Rise on Balance Sheet Strengthening
By Colin Kellaher Omeros shares rose sharply Monday after the biopharmaceutical company unveiled a series of financial transactions that bolstered its balance sheet and extended the maturity of a sub
Express News | Omeros Corp: Entered Credit Agreement Which Provides for a Senior Secured Term Loan Facility Initially of up to $92.1 Mln
Omeros Corporation Further Strengthens Its Balance Sheet Through Series of Financing Transactions Extending Maturity on a Majority of Its Outstanding Debt Into 2028
Omeros Corporation (Nasdaq: OMER) today announced that it has completed a series of strategic financial transactions, further strengthening its balance sheet and extending the maturity profile on a substantial portion of its debt from February 2026 to June 2028, while providing a secure source of capital to support potential commercialization of its lectin pathway inhibitor narsoplimab and flexibility to manage the remaining balance of 2026 convertible notes.
Health Care Flat as Momentum Wanes -- Health Care Roundup
Health-care companies were flat as momentum in the sector stalled. Obesity drug maker Novo Nordisk and Eli Lilly gave back some of their recent gains. Omeros shares tumbled after the clinical-stage b
Why Fluent Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fluent Inc (NASDAQ:FLNT) fell sharply during Thursday's session after posting weaker-than-expected quarterly results.Fluent posted adjusted loss of 30 cents per share, versus market expectat
SYTA, DATS and CYN Among Mid-day Movers
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersLucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. SINTX Techs (NASDAQ:SINT) sha
Express News | Omeros Shares Down 20.4% After Q1 Results
Omeros Plunges 20% Following Q1 Report, Drug Update
Express News | Omeros Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Adjusted EPS Results
Express News | Needham Reiterates Hold on Omeros
Omeros Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 — Needham Reiterates → Hold 11/10/2023 — Cantor Fitzgerald Downgrades Overweight → Neutral 12
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Cullinan Management (CGEM) and Omeros (OMER)
Omeros (OMER) Gets a Hold From Needham
Omeros | 10-Q: Quarterly report
Omeros 1Q Loss/Shr 63c >OMER
Omeros 1Q Loss/Shr 63c >OMER
Express News | Omeros Corporation Q1 Net Income USD -37.2 Million
Express News | Omeros Corporation Q1 EPS USD -0.63
Express News | Omeros Corporation Reports First Quarter 2024 Financial Results
Express News | Omeros Corporation Q1 Net Income Continuing Operations USD -43.9 Million
No Data